Digital technology helps patients with complex needs Digital technology helps patients with complex needs Digital technology helps patients with complex needs
Using AI to transform screening for type 2 diabetes Using AI to transform screening for type 2 diabetes Using AI to transform screening for type 2 diabetes
Supporting Sustainable Healthcare Supporting Sustainable Healthcare Supporting Sustainable Healthcare
Partnering at Boehringer Ingelheim Canada Partnering at Boehringer Ingelheim Canada Partnering at Boehringer Ingelheim Canada
The Type 2 Spark Innovation Challenge The Type 2 Spark Innovation Challenge The Type 2 Spark Innovation Challenge
Partnering at Boehringer Ingelheim Canada Partnering at Boehringer Ingelheim Canada Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada Partnering at Boehringer Ingelheim Canada Partnering at Boehringer Ingelheim Canada
Helping patients by addressing health system gaps Helping patients by addressing health system gaps Helping patients by addressing health system gaps
New analytical tool helps optimize patient care New analytical tool helps optimize patient care New analytical tool helps optimize patient care
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
Laura loves her diverse career Laura loves her diverse career Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Ann-Kathrin Koller Ann-Kathrin Koller Career choices, culture, the future and more with Ann-Kathrin Koller.